- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/755 - Facteurs VIII
Détention brevets de la classe C07K 14/755
Brevets de cette classe: 842
Historique des publications depuis 10 ans
|
84
|
65
|
88
|
64
|
53
|
52
|
49
|
41
|
46
|
25
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Bioverativ Therapeutics Inc. | 211 |
86 |
| Takeda Pharmaceutical Company Limited | 2712 |
57 |
| Octapharma AG | 200 |
27 |
| The Children's Hospital of Philadelphia | 857 |
22 |
| Novo Nordisk A/S | 2279 |
21 |
| The Trustees of the University of Pennsylvania | 4415 |
15 |
| CSL Limited | 246 |
15 |
| St. Jude Children's Research Hospital | 236 |
15 |
| CSL Behring Lengnau AG | 125 |
15 |
| CSL Behring GmbH | 346 |
14 |
| Bayer HealthCare LLC | 1307 |
12 |
| Baxalta Incorporated | 297 |
12 |
| Emory University | 1719 |
12 |
| Baxalta GmbH | 102 |
11 |
| UCL Business Ltd | 676 |
11 |
| Baxter International Inc. | 1891 |
10 |
| Baxter Healthcare S.A. | 1394 |
10 |
| Georgia Tech Research Corporation | 2943 |
10 |
| BioMarin Pharmaceutical Inc. | 400 |
10 |
| Spark Therapeutics, Inc. | 182 |
9 |
| Autres propriétaires | 448 |